Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab.
Yi-Qun CheYue ZhangKai-Ping OuDi WangDi ShenHui-Ying LiuYang LuoPublished in: Cancer management and research (2020)
ETS≥30% and DepRe≥40% were significant predictors of better clinical outcomes in mBC patients treated with first-line trastuzumab-based chemotherapy. Further validation in prospective trials with larger patient populations is needed.